Radioactive drug before and after surgery may improve outcomes for rare gut cancers

NCT ID NCT04609592

First seen Sep 30, 2025 · Last updated May 01, 2026 · Updated 26 times

Summary

This early-phase study tests whether giving a radioactive drug (Lutathera) both before and after surgery is safe and feasible for people with metastatic neuroendocrine tumors of the gut or pancreas. About 10 adults with slow-growing tumors that have spread to lymph nodes or liver will receive two cycles of the drug, then surgery, then more drug. The goal is to see if this approach can reduce complications and improve tumor control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Stanford Cancer Institute Palo Alto

    RECRUITING

    Stanford, California, 95304, United States

    Contact Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.